Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rota-V-Aid
- Development stage
- Unknown
- Lead developer
- Pharm Aid
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
**Rota-V-Aid** is an orally administered, freeze-dried, live-attenuated pentavalent rotavirus vaccine licensed from Serum Institute of India and developed for the Russian market by Pharm Aid. It contains human-bovine rotavirus reassortants representing G1, G2, G3, G4, and G9 types, grown in Vero cells, and is intended to prevent rotavirus gastroenteritis in infants through a three-dose oral immunization series. ([pharmaid.com](https://pharmaid.com/en/products/rota-v-ejd/))
- Brand names
- Rota-V-AidRotasiil
- Other names
- Рота-V-Эйд
02
Targets
VP7 (Rotavirus VP7)
Beyond the preview
Go deeper on Rota-V-Aid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rota-V-Aid.